Krabbe Disease Treatment Market by Therapy and Geography - Forecast and Analysis 2022-2026

Published: Apr 2022 Pages: 120 SKU: IRTNTR73314

The predicted growth of the krabbe disease treatment market share from 2021 to 2026 is USD 438.03 million at a progressing CAGR of 7.56%

This krabbe disease treatment market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers krabbe disease treatment market segmentation by:

  • Therapy - Anticonvulsants, muscle relaxants, HSCT, and others
  • Geography - North America, Europe, Asia, and Rest of World (ROW)

The krabbe disease treatment market report also offers information on several market vendors, including AbbVie Inc., Acorda Therapeutics Inc., CENTOGENE NV, GlaxoSmithKline Plc, Johnson and Johnson, Novartis AG, Pfizer Inc., Polaryx, Teva Pharmaceutical Industries Ltd., and UCB SA among others.

What will the Krabbe Disease Treatment Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Krabbe Disease Treatment Market Size for the Forecast Period and Other Important Statistics

 

Krabbe Disease Treatment Market: Key Drivers, Trends, and Challenges

The special drug designation is notably driving the krabbe disease treatment market growth, although factors such as limited patient pool for clinical trials may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the krabbe disease treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Krabbe Disease Treatment Market Driver

One of the key factors driving growth in the krabbe disease treatment market is the special drug designation. The priority review program for facilitating fast drug approvals is offered by the Food and Drug Administration (FDA). This program entitles a sponsor to obtain a priority review voucher on receiving an approval for a biologic or drug for a rare pediatric disease. The voucher helps the sponsor to get the priority review of a subsequent marketing application for a different product. Such special drug designations act as a non-monetary motivation factor for the vendor to engage in R and D for rare diseases such as Krabbe. With the disease being rare and the patient pool small (factors responsible for low profits), such designations make the otherwise non-viable deal, attractive for the vendors. Hence, such special designations will drive market growth during the forecast period.

Key Krabbe Disease Treatment Market Trend

The emergence of pharmacological chaperone therapy is a krabbe disease treatment market trend that is expected to have a positive impact in the coming years. A missense mutation in the GLC enzyme is responsible for more than two-fifths of all known instances of Krabbe disease. Due to the lack of accumulated main substrate within the lysosome and the predominant CNS illness, therapeutic techniques for other lysosomal storage disorders are ineffective in treating Krabbe disease. Due to specific qualities such as low molecular weight, low toxicity, and high bioavailability, the molecules are being studied because they have the potential to penetrate the blood-brain barrier more efficiently than enzymes. There have also been some allosteric chaperones discovered that are directed away from the enzyme's active site. Krabbe disease may be treated with pharmacological chaperone therapy, which is likely to be effective.

Key Krabbe Disease Treatment Market Challenge

The limited patient pool for clinical trials will be a major challenge for the krabbe disease treatment market during the forecast period. Orphan diseases like Krabbe have a very low prevalence rate. As a result, compared to other conditions, the percentage of the population affected by such diseases is low. The number of people available for clinical trials of medications being developed for the treatment of orphan diseases is limited. Due to the lack of a patient pool, drugs examined in these studies also fail to show statistically significant results, even if they are effective. Because it is difficult to identify people from all areas and races due to the rarity of the disease's rarity, limited enrolment in clinical trials raises the risk of post-marketing adverse effects. Trials comparing new treatments to existing medications necessitate a large patient population, which is yet another constraint for the global Krabbe disease treatment market.

This krabbe disease treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global Krabbe disease treatment market as a part of the global pharmaceuticals market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the krabbe disease treatment market during the forecast period.

Who are the Major Krabbe Disease Treatment Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

  • AbbVie Inc.
  • Acorda Therapeutics Inc.
  • CENTOGENE NV
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • Novartis AG
  • Pfizer Inc.
  • Polaryx
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA

 

This statistical study of the krabbe disease treatment market encompasses successful business strategies deployed by the key vendors. The krabbe disease treatment market is concentrated and the vendors are deploying growth strategies such as practicing efficient production techniques to minimize treatment costs and prevent cost overruns to compete in the market.

Product Insights and News

  • jnj.com - The company offers Flexeril as muscle relaxants for krabbe disease treatment.

  • jnj.com - The consumer segment is focused on six therapeutic areas, immunology, neuroscience, infectious diseases and vaccines, oncology, cardiovascular and metabolism, and pulmonary hypertension.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The krabbe disease treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Krabbe Disease Treatment Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the krabbe disease treatment market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Krabbe Disease Treatment Market?

For more insights on the market share of various regions Request for a FREE sample now!

37% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for krabbe disease treatment in North America. Market growth in this region will be slower than the growth of the market in other regions.

The significant incidence rate of Krabbe disease will facilitate the krabbe disease treatment market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The outbreak of COVID-19 drastically affected the Krabbe disease treatment in the region. This led to radical changes and disturbances like delay or cancellation in treatment in various medical procedures. Owing to the pandemic, all the medical procedures and services, including Krabbe disease treatment, are performed in compliance with all COVID-19 measures and precautions. The fear of the spread of COVID-19 among people reduced, which, in turn, will drive the growth of the regional market during the forecast period.

What are the Revenue-generating Therapy Segments in the Krabbe Disease Treatment Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The krabbe disease treatment market share growth by the anticonvulsants segment will be significant during the forecast period. Anticonvulsant drugs are used for the treatment of convulsions or seizures, which is one of the main symptoms of Krabbe disease in infants. Convulsions occur due to severe myelin destruction. With no treatment available to change the course of the disease, there is a high demand for anticonvulsants to treat convulsions that occur in Krabbe-affected patients.

This report provides an accurate prediction of the contribution of all the segments to the growth of the krabbe disease treatment market size and actionable market insights on post COVID-19 impact on each segment.

 

Krabbe Disease Treatment Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 7.56%

Market growth 2022-2026

$ 438.03 million

Market structure

Concentrated

YoY growth (%)

7.34

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 37%

Key consumer countries

US, Canada, UK, Germany, Japan, and China

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

AbbVie Inc., Acorda Therapeutics Inc., CENTOGENE NV, GlaxoSmithKline Plc, Johnson and Johnson, Novartis AG, Pfizer Inc., Polaryx, Teva Pharmaceutical Industries Ltd., and UCB SA

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Krabbe Disease Treatment Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive krabbe disease treatment market growth during the next five years
  • Precise estimation of the krabbe disease treatment market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the krabbe disease treatment industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market's competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of krabbe disease treatment market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 17: Five forces analysis - Comparison between2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Therapy

    • 5.1 Market segments
      • Exhibit 24: Chart on Therapy - Market share 2021-2026 (%)
      • Exhibit 25: Data Table on Therapy - Market share 2021-2026 (%)
    • 5.2 Comparison by Therapy
      • Exhibit 26: Chart on Comparison by Therapy
      • Exhibit 27: Data Table on Comparison by Therapy
    • 5.3 Anticonvulsants - Market size and forecast 2021-2026
      • Exhibit 28: Chart on Anticonvulsants - Market size and forecast 2021-2026 ($ million)
      • Exhibit 29: Data Table on Anticonvulsants - Market size and forecast 2021-2026 ($ million)
      • Exhibit 30: Chart on Anticonvulsants - Year-over-year growth 2021-2026 (%)
      • Exhibit 31: Data Table on Anticonvulsants - Year-over-year growth 2021-2026 (%)
    • 5.4 Muscle relaxants - Market size and forecast 2021-2026
      • Exhibit 32: Chart on Muscle relaxants - Market size and forecast 2021-2026 ($ million)
      • Exhibit 33: Data Table on Muscle relaxants - Market size and forecast 2021-2026 ($ million)
      • Exhibit 34: Chart on Muscle relaxants - Year-over-year growth 2021-2026 (%)
      • Exhibit 35: Data Table on Muscle relaxants - Year-over-year growth 2021-2026 (%)
    • 5.5 HSCT - Market size and forecast 2021-2026
      • Exhibit 36: Chart on HSCT - Market size and forecast 2021-2026 ($ million)
      • Exhibit 37: Data Table on HSCT - Market size and forecast 2021-2026 ($ million)
      • Exhibit 38: Chart on HSCT - Year-over-year growth 2021-2026 (%)
      • Exhibit 39: Data Table on HSCT - Year-over-year growth 2021-2026 (%)
    • 5.6 Others - Market size and forecast 2021-2026
      • Exhibit 40: Chart on Others - Market size and forecast 2021-2026 ($ million)
      • Exhibit 41: Data Table on Others - Market size and forecast 2021-2026 ($ million)
      • Exhibit 42: Chart on Others - Year-over-year growth 2021-2026 (%)
      • Exhibit 43: Data Table on Others - Year-over-year growth 2021-2026 (%)
    • 5.7 Market opportunity by Therapy
      • Exhibit 44: Market opportunity by Therapy ($ million)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 46: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 47: Data Table on Market share by geography 2021-2026 (%)
    • 7.2 Geographic comparison
      • Exhibit 48: Chart on Geographic comparison
      • Exhibit 49: Data Table on Geographic comparison
    • 7.3 North America - Market size and forecast 2021-2026
      • Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 7.4 Europe - Market size and forecast 2021-2026
      • Exhibit 54: Chart on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 55: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 56: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 7.5 Asia - Market size and forecast 2021-2026
      • Exhibit 58: Chart on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 59: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 60: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 61: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 7.7 US - Market size and forecast 2021-2026
      • Exhibit 66: Chart on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 67: Data Table on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 68: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 69: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 7.8 Canada - Market size and forecast 2021-2026
      • Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
      • Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
    • 7.9 UK - Market size and forecast 2021-2026
      • Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 7.10 Germany - Market size and forecast 2021-2026
      • Exhibit 78: Chart on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 79: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 80: Chart on Germany - Year-over-year growth 2021-2026 (%)
      • Exhibit 81: Data Table on Germany - Year-over-year growth 2021-2026 (%)
    • 7.11 Japan - Market size and forecast 2021-2026
      • Exhibit 82: Chart on Japan - Market size and forecast 2021-2026 ($ million)
      • Exhibit 83: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
      • Exhibit 84: Chart on Japan - Year-over-year growth 2021-2026 (%)
      • Exhibit 85: Data Table on Japan - Year-over-year growth 2021-2026 (%)
    • 7.12 China - Market size and forecast 2021-2026
      • Exhibit 86: Chart on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 87: Data Table on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 88: Chart on China - Year-over-year growth 2021-2026 (%)
      • Exhibit 89: Data Table on China - Year-over-year growth 2021-2026 (%)
    • 7.13 Market opportunity by geography
      • Exhibit 90: Market opportunity by geography ($ million)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • 8.3 Impact of drivers and challenges
          • Exhibit 91: Impact of drivers and challenges in 2021 and 2026
        • 8.4 Market trends

          9 Vendor Landscape

          • 9.1 Overview
            • 9.2 Vendor landscape
              • Exhibit 92: Overview on Criticality of inputs and Factors of differentiation
            • 9.3 Landscape disruption
              • Exhibit 93: Overview on factors of disruption
            • 9.4 Industry risks
              • Exhibit 94: Impact of key risks on business

            10 Vendor Analysis

            • 10.1 Vendors covered
              • Exhibit 95: Vendors covered
            • 10.2 Market positioning of vendors
              • Exhibit 96: Matrix on vendor position and classification
            • 10.3 AbbVie Inc.
              • Exhibit 97: AbbVie Inc. - Overview
              • Exhibit 98: AbbVie Inc. - Product / Service
              • Exhibit 99: AbbVie Inc. - Key offerings
            • 10.4 Acorda Therapeutics Inc.
              • Exhibit 100: Acorda Therapeutics Inc. - Overview
              • Exhibit 101: Acorda Therapeutics Inc. - Business segments
              • Exhibit 102: Acorda Therapeutics Inc. - Key offerings
              • Exhibit 103: Acorda Therapeutics Inc. - Segment focus
            • 10.5 CENTOGENE NV
              • Exhibit 104: CENTOGENE NV - Overview
              • Exhibit 105: CENTOGENE NV - Key offerings
            • 10.6 GlaxoSmithKline Plc
              • Exhibit 106: GlaxoSmithKline Plc - Overview
              • Exhibit 107: GlaxoSmithKline Plc - Business segments
              • Exhibit 108: GlaxoSmithKline Plc - Key news
              • Exhibit 109: GlaxoSmithKline Plc - Key offerings
              • Exhibit 110: GlaxoSmithKline Plc - Segment focus
            • 10.7 Johnson and Johnson
              • Exhibit 111: Johnson and Johnson - Overview
              • Exhibit 112: Johnson and Johnson - Business segments
              • Exhibit 113: Johnson and Johnson - Key news
              • Exhibit 114: Johnson and Johnson - Key offerings
              • Exhibit 115: Johnson and Johnson - Segment focus
            • 10.8 Novartis AG
              • Exhibit 116: Novartis AG - Overview
              • Exhibit 117: Novartis AG - Business segments
              • Exhibit 118: Novartis AG - Key offerings
              • Exhibit 119: Novartis AG - Segment focus
            • 10.9 Pfizer Inc.
              • Exhibit 120: Pfizer Inc. - Overview
              • Exhibit 121: Pfizer Inc. - Product / Service
              • Exhibit 122: Pfizer Inc. - Key news
              • Exhibit 123: Pfizer Inc. - Key offerings
            • 10.10 Polaryx
              • Exhibit 124: Polaryx - Overview
              • Exhibit 125: Polaryx - Product / Service
              • Exhibit 126: Polaryx - Key offerings
            • 10.11 Teva Pharmaceutical Industries Ltd.
              • Exhibit 127: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 128: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 129: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 130: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 131: Teva Pharmaceutical Industries Ltd. - Segment focus
            • 10.12 UCB SA
              • Exhibit 132: UCB SA - Overview
              • Exhibit 133: UCB SA - Product / Service
              • Exhibit 134: UCB SA - Key offerings

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Inclusions and exclusions checklist
                • Exhibit 135: Inclusions checklist
                • Exhibit 136: Exclusions checklist
              • 11.3 Currency conversion rates for US$
                • Exhibit 137: Currency conversion rates for US$
              • 11.4 Research methodology
                • Exhibit 138: Research methodology
                • Exhibit 139: Validation techniques employed for market sizing
                • Exhibit 140: Information sources
              • 11.5 List of abbreviations
                • Exhibit 141: List of abbreviations

                Research Framework

                Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

                INFORMATION SOURCES

                Primary sources

                • Manufacturers and suppliers
                • Channel partners
                • Industry experts
                • Strategic decision makers

                Secondary sources

                • Industry journals and periodicals
                • Government data
                • Financial reports of key industry players
                • Historical data
                • Press releases

                DATA ANALYSIS

                Data Synthesis

                • Collation of data
                • Estimation of key figures
                • Analysis of derived insights

                Data Validation

                • Triangulation with data models
                • Reference against proprietary databases
                • Corroboration with industry experts

                REPORT WRITING

                Qualitative

                • Market drivers
                • Market challenges
                • Market trends
                • Five forces analysis

                Quantitative

                • Market size and forecast
                • Market segmentation
                • Geographical insights
                • Competitive landscape

                PURCHASE FULL REPORT OF

                krabbe disease treatment market

                QUICK BUY

                Key Questions Answered

                • What are the key global market and the regional market share?
                • What are the revenue-generating key market segments?
                • What are the key factors driving and challenging this market’s growth?
                • Who are the key market vendors and their growth strategies?
                • What are the latest trends influencing the growth of this market?
                • What are the variables influencing the market growth in the primary regions?
                • What are the factors influencing the growth of the parent market?

                Why should you prefer Technavio's market insights report?

                • Off-the-shelf research reports
                • Reports can be tailored to meet the customer's needs
                • Trusted by more than 100 fortune 500 organizations
                • Information about the market's key drivers, trends, and challenges
                • Parent market analysis
                • Every week, 50,000 people visit our subscription platform
                • Detailed vendors report with competitive landscape
                • Covid-19 impact and recovery analysis
                • Data on revenue-generating market segments
                • Details on the market shares of various regions
                • Five-force market analysis